Deciphering the clinical presentations, pathogenesis, and treatment of the idiopathic inflammatory myopathies.
about
Biomarkers and Autoantibodies of Interstitial Lung Disease with Idiopathic Inflammatory MyopathiesDevelopments in the classification and treatment of the juvenile idiopathic inflammatory myopathiesEpidemiology of environmental exposures and human autoimmune diseases: findings from a National Institute of Environmental Health Sciences Expert Panel WorkshopIdiopathic Inflammatory Myopathies and Malignancy: a Comprehensive Review.Genome-wide association study identifies HLA 8.1 ancestral haplotype alleles as major genetic risk factors for myositis phenotypes.Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial.An overview of polymyositis and dermatomyositis.The composition of cellular infiltrates in anti-HMG-CoA reductase-associated myopathy.Laboratory Test Abnormalities are Common in Polymyositis and Dermatomyositis and Differ Among Clinical and Demographic Groups.The clinical phenotypes of the juvenile idiopathic inflammatory myopathies.Increased Risk of Herpes Zoster Following Dermatomyositis and Polymyositis: A Nationwide Population-Based Cohort Study.Myositis-specific autoantibodies are specific for myositis compared to genetic muscle disease.Magnetic resonance measurement of muscle T2, fat-corrected T2 and fat fraction in the assessment of idiopathic inflammatory myopathies.Investigation into the cause of mortality in 49 cases of idiopathic inflammatory myopathy: A single center studyCytosolic 5'-Nucleotidase 1A As a Target of Circulating Autoantibodies in Autoimmune DiseasesThe juvenile idiopathic inflammatory myopathies: pathogenesis, clinical and autoantibody phenotypes, and outcomesThe myositis autoantibody phenotypes of the juvenile idiopathic inflammatory myopathies.Brief report: ultraviolet radiation exposure is associated with clinical and autoantibody phenotypes in juvenile myositis.Genome-wide association study of dermatomyositis reveals genetic overlap with other autoimmune disorders.Acute Presentation of Juvenile Dermatomyositis with Subclinical Cardiac Involvement: A Rare Case.Clinical features, pathogenesis and treatment of juvenile and adult dermatomyositis.Myositis Mimics.Current pharmacological treatment of idiopathic inflammatory myopathies.2016 American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatri2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric RheumatologyExtreme elevation of ferritin and creatine kinase in primary infection with HIV-1.Integrated classification of inflammatory myopathies.Muscle myeloid type I interferon gene expression may predict therapeutic responses to rituximab in myositis patients.Practical approach to the patient with acute neuromuscular weakness.Heterogeneous clinical spectrum of anti-SRP myositis and importance of the methods of detection of anti-SRP autoantibodies: a multicentric study.Overlapping features of polymyositis and inclusion body myositis in HIV-infected patients.Gene copy-number variations (CNVs) of complement C4 and C4A deficiency in genetic risk and pathogenesis of juvenile dermatomyositis.Dense genotyping of immune-related loci in idiopathic inflammatory myopathies confirms HLA alleles as the strongest genetic risk factor and suggests different genetic background for major clinical subgroups.213th ENMC International Workshop: Outcome measures and clinical trial readiness in idiopathic inflammatory myopathies, Heemskerk, The Netherlands, 18-20 September 2015Single nucleotide polymorphisms in the ETS1 gene are associated with idiopathic inflammatory myopathies in a northern Chinese Han populationAssociation of Anti-3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Autoantibodies With DRB1*07:01 and Severe Myositis in Juvenile Myositis Patients.Statin-associated Autoimmune Myopathies: A Pathophysiologic Spectrum.2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Adult Dermatomyositis and Polymyositis: An International Myositis Assessment and Clinical Studies Group/PaediatriAnti-NT5C1A autoantibodies are associated with more severe disease in patients with juvenile myositis.Anti-MDA5 antibody is associated with A/SIP and decreased T cells in peripheral blood and predicts poor prognosis of ILD in Chinese patients with dermatomyositis.
P2860
Q26824432-50CF761D-825B-4F1D-B1E9-EEBC66379D48Q26863125-5B154B5D-4103-4B79-97DF-EA23B73527CBQ28390922-431CE621-C95D-468F-BA63-339C6A2A2FC0Q30252086-48BCF7F0-7620-47B8-A334-8FF14668B82BQ34490287-8DAA5193-2255-42B8-A8ED-FA2EB893A62DQ34644962-9DBAD840-67FC-4712-8E19-E65DC27E9FEFQ34667765-F64AF5E0-7A0E-4F0D-9E90-60D3156ADDD5Q35876136-23F51EAC-F080-4EFB-855D-E6D524D7FC54Q36041178-ED6F0F50-389E-44F7-A9D8-EB50C016C7D7Q36086954-860EF4A7-32FB-4932-8CD9-57F447062315Q36196678-D10B21A7-9F2D-4BC8-BF1B-95214265DE7EQ36364785-29EBA5CB-94BA-4888-A205-40C8509A06A7Q36591665-B33FABC6-6B28-4203-B1E2-3E91C3621DC1Q36639876-FED310A5-2D05-477C-9BBB-0A9F8E6AE304Q36953554-E22B6E3F-5174-4B54-A9C7-BB1ED1EE8310Q37022721-DA5881B3-F66E-4469-82EC-B70191BBEBBCQ37040711-C4EF0022-43F8-4B6F-9B7B-8F5E98D3F207Q37056716-0AF177AE-F8D9-4AF6-BA1D-42F39A9E8E22Q37601815-D5439701-579E-47F7-9E61-017D080FEA1BQ37630165-25B85E49-8265-4924-A801-59A602A7136EQ37938701-D4FDF81E-4957-4BA3-BFC1-B9E68E8587F9Q38569863-6CDBA2BD-7FB2-464C-B68F-6D0AAFFD973DQ38680762-FE3DCB87-3A9B-4C37-A521-662FFCADD46FQ38849144-7281D139-2A1A-4651-82C7-AAAED4E84DB7Q38849148-23119911-DD7E-4671-92B5-1339CBF53287Q38886610-DA23F5AC-AEB4-442B-9614-8CED7ED5ED85Q39027323-209EA1B9-943C-4F1D-B514-CEC625ADA18CQ39742692-5BA47FE2-911C-4125-8746-53880D609C65Q40043727-F4658353-536D-4E5E-A963-3936D31831DAQ40130278-CC5DE948-23CA-45D9-B953-4EA11EEFCE5AQ40298726-E547AEB8-DA60-4C61-9950-38525134DC7CQ41192731-E3646B9C-143F-4075-B783-FDE0D9ED2E29Q42098903-663C7BAA-8943-4A0D-B3E0-8B5E410557A2Q42365042-E37F2B11-179B-4011-9E53-5F914E9A94A0Q42377281-AFC8891D-39DF-4F9D-9D0C-B395ED931232Q45969468-1DDAC4B4-1C24-4ACA-A317-C3FAA6D62E0DQ46066815-B81AA46E-27CB-4165-B28A-FCD7CBAB1F8BQ46815762-113EFB51-63F5-474F-A519-3B39C3CF6798Q47648163-CBCF1CB5-88C0-495A-9030-7E300955526BQ54540683-982AB36A-0B1B-4469-AF2A-144AEE32B23D
P2860
Deciphering the clinical presentations, pathogenesis, and treatment of the idiopathic inflammatory myopathies.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Deciphering the clinical prese ...... athic inflammatory myopathies.
@ast
Deciphering the clinical prese ...... athic inflammatory myopathies.
@en
type
label
Deciphering the clinical prese ...... athic inflammatory myopathies.
@ast
Deciphering the clinical prese ...... athic inflammatory myopathies.
@en
prefLabel
Deciphering the clinical prese ...... athic inflammatory myopathies.
@ast
Deciphering the clinical prese ...... athic inflammatory myopathies.
@en
P2860
P356
P1476
Deciphering the clinical prese ...... pathic inflammatory myopathies
@en
P2093
Lisa G Rider
P2860
P304
P356
10.1001/JAMA.2010.1977
P407
P577
2011-01-01T00:00:00Z